Table 1.
Study cohort of HBeAg negative patients with chronic HBV infection
| Characteristics | Patients with chronic HBV infection (n=57) | ||||||
| HBsAg groups (IU/mL) | HBcrAg groups (Log U/mL) | ||||||
| <100 | 100–1000 | 1000–10 000 | ≥10 000 | <3 | 3–3.87 | ≥3.87 | |
| Number of patients | 14 | 12 | 14 | 17 | 32 | 13 | 12 |
| HBsAg (IU/mL): median (range) | 34.5 (0.2–97) | 329.5 (159–835) | 3215.5 (1301–8455) | 17 761 (10 375–45 634) | 297 (0.2–34 727) | 7061 (326–31 677) | 7725.5 (214–45 634) |
| HBcrAg (LogU/ml): median (range) | 2.4 (2–2.8) | 2.6 (2–5.5) | 3.25 (2–5.7) | 3.3 (2–8.2) | 2.4 (2–2.9) | 3.1 (3–3.7) | 5.1 (3.9–8.2) |
| Sex (male/female) | 8/6 | 8/4 | 9/5 | 9/8 | 17/15 | 8/5 | 9/3 |
| Age (years): median (range) | 44.5 (28–72) | 43.5 (31–60) | 41 (22–70) | 42 (18–70) | 42.5 (23–72) | 44 (18–70) | 39.5 (19–67) |
| ALT level (IU/L): median (range) | 24 (13–84) | 22.5 (15–58) | 29 (14–220) | 33 (13–128) | 24.5 (13–84) | 22 (13–54) | 56.5 (19–220) |
| HBV DNA <2000 IU/mL (%) | 92.9 | 91.7 | 78.6 | 58.8 | 90.6 | 84.6 | 41.7 |
| HBeAg (–/+/n.d.) | 14/0/0 | 11/0/1 | 13/0/1 | 16/0/1 | 32/0/0 | 12/0/1 | 10/0/2 |
| NA therapy yes/no | 3/11 | 6/6 | 6/8 | 3/14 | 7/25 | 5/8 | 6/6 |
ALT, alanine transaminase; HBcrAg, hepatitis B core-related antigen; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; NA, nucleos(t)ide analogue; n.d., not determined.